Chimeric antigen receptor (CAR) T-cell therapy: Harnessing extracellular vesicles for enhanced efficacy
A cutting-edge approach in cell-based immunotherapy for combating resistant cancer involves genetically engineered chimeric antigen receptor T (CAR-T) lymphocytes. In recent years, these therapies have demonstrated effectiveness, leading to their commercialization and clinical application against ce...
Saved in:
Main Authors: | Beatrice Spokeviciute (Author), Sharad Kholia (Author), Maria Felice Brizzi (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2024-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Chimeric Antigen Receptor (CAR)-T Cell Therapy for Non-Hodgkin's Lymphoma
by: Maria Giraudo, et al.
Published: (2024) -
Site-specific transgene integration in chimeric antigen receptor (CAR) T cell therapies
by: Hamed Dabiri, et al.
Published: (2023) -
TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
by: Zakaria Grada, et al.
Published: (2013) -
Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects
by: Javad Masoumi, et al.
Published: (2021) -
Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T‐cellular therapy development
by: Johannes Kast, et al.
Published: (2022)